BR0312437A - Polipeptìdeo imunogênico isolado mycobacterium avium subspécie para tuberculosis e usos do mesmo - Google Patents

Polipeptìdeo imunogênico isolado mycobacterium avium subspécie para tuberculosis e usos do mesmo

Info

Publication number
BR0312437A
BR0312437A BR0312437A BR0312437A BR0312437A BR 0312437 A BR0312437 A BR 0312437A BR 0312437 A BR0312437 A BR 0312437A BR 0312437 A BR0312437 A BR 0312437A BR 0312437 A BR0312437 A BR 0312437A
Authority
BR
Brazil
Prior art keywords
mycobacterium avium
polypeptide
immunogenic polypeptide
tuberculosis
avium subspecies
Prior art date
Application number
BR0312437A
Other languages
English (en)
Other versions
BRPI0312437B1 (pt
Inventor
Alan Murray Clark
Christine Dupont
Original Assignee
Univ Massey
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Massey, Pasteur Institut filed Critical Univ Massey
Publication of BR0312437A publication Critical patent/BR0312437A/pt
Publication of BRPI0312437B1 publication Critical patent/BRPI0312437B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"POLIPEPTìDEO IMUNOGêNICO ISOLADO DE MYCOBACTERIUM AVIUM SUBESPéCIE PARATUBERCULOSIS E USOS DO MESMO". A presente invenção refere-se a um polipeptídeo imunogênico isolado de mycobacterium avium subspécie paratuberculosis e vadantes do polipeptídeo. O polipeptídeo e variantes podem ser usados contra doença de Johne e em métodos para detecção de doença. Anticorpos contra polipeptídeos ou variantes podem ser usados em testes diagnósticos para doença de Johne. Polinucleotídeos codificando polipeptídeo e variantes e métodos para preparação dos mesmos também são incluídos.
BRPI0312437A 2002-06-19 2003-06-19 constructo genético, célula, composições de vacina e de diagnóstico para presença de mycobaterium avium subespécie paratuberculosis, e métodos de detecção da doença de johne BRPI0312437B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ519667A NZ519667A (en) 2002-06-19 2002-06-19 A putative 23kDa lipoprotein from Mycobacterium paratuberculosis and its use in Johne's disease
PCT/NZ2003/000125 WO2004000878A1 (en) 2002-06-19 2003-06-19 Immunogenic polypeptide isolated from Mycobacterium avium subspecies paratuberculosis and uses thereof

Publications (2)

Publication Number Publication Date
BR0312437A true BR0312437A (pt) 2005-05-03
BRPI0312437B1 BRPI0312437B1 (pt) 2015-09-22

Family

ID=29997599

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0312437A BRPI0312437B1 (pt) 2002-06-19 2003-06-19 constructo genético, célula, composições de vacina e de diagnóstico para presença de mycobaterium avium subespécie paratuberculosis, e métodos de detecção da doença de johne

Country Status (7)

Country Link
US (2) US7744905B2 (pt)
EP (1) EP1539810B1 (pt)
AU (1) AU2003238755B2 (pt)
BR (1) BRPI0312437B1 (pt)
CA (1) CA2491070C (pt)
NZ (2) NZ519667A (pt)
WO (1) WO2004000878A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008033806A1 (en) * 2006-09-11 2008-03-20 University Of Florida Research Foundation, Inc. Mycobacterium avium subspecies paratuberculosis (map) diagnostic test
KR20100042082A (ko) * 2008-10-15 2010-04-23 삼성전자주식회사 신호물질의 밀도가 증가되어 있는 고체 지지체, 그를 포함하는 키트 및 그를 이용한 표적물질 검출 방법
US20140116353A1 (en) * 2012-10-31 2014-05-01 Gilles R.G. Monif Fuidi herd management and risk stratification methods
US9128098B2 (en) 2012-10-31 2015-09-08 Gilles R. G. Monif Fuidi herd management and risk stratification methods
CN111323594B (zh) * 2020-02-19 2021-02-02 武汉华美生物工程有限公司 一种提高兔抗血清的抗体特异性的蛋白质免疫印迹检测方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2767337B1 (fr) 1997-08-14 2002-07-05 Pasteur Institut Sequences nucleiques de polypeptides exportes de mycobacteri es, vecteurs les comprenant et applications au diagnostic et a la prevention de la tuberculose
AU2594500A (en) * 1998-12-24 2000-07-31 Corixa Corporation Methods for using mycobacterium tuberculosis molecules as immunological adjuvants
NZ513418A (en) * 2001-08-07 2004-04-30 Univ Massey Vaccine comprising proteins from mycobacterium paratuberculosis

Also Published As

Publication number Publication date
NZ519667A (en) 2005-02-25
BRPI0312437B1 (pt) 2015-09-22
US9102743B2 (en) 2015-08-11
WO2004000878A1 (en) 2003-12-31
EP1539810B1 (en) 2017-12-20
CA2491070A1 (en) 2003-12-31
US7744905B2 (en) 2010-06-29
AU2003238755A1 (en) 2004-01-06
EP1539810A4 (en) 2005-12-14
NZ537535A (en) 2007-06-29
EP1539810A1 (en) 2005-06-15
US20060210578A1 (en) 2006-09-21
US20100330560A1 (en) 2010-12-30
AU2003238755B2 (en) 2009-11-12
CA2491070C (en) 2017-07-25

Similar Documents

Publication Publication Date Title
Okkels et al. PPE protein (Rv3873) from DNA segment RD1 of Mycobacterium tuberculosis: strong recognition of both specific T-cell epitopes and epitopes conserved within the PPE family
Colangeli et al. MTSA-10, the product of the Rv3874 gene of Mycobacterium tuberculosis, elicits tuberculosis-specific, delayed-type hypersensitivity in guinea pigs
Diel et al. Avoiding the effect of BCG vaccination in detecting Mycobacterium tuberculosis infection with a blood test
US9844604B2 (en) Proteins expressed by Mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents and vaccines
Majlessi et al. CD8+-T-CellResponses of Mycobacterium-Infected Mice to a Newly Identified MajorHistocompatibility Complex Class I-Restricted Epitope Shared byProteins of the ESAT-6Family
Aagaard et al. Genomic approach to identification of Mycobacterium bovis diagnostic antigens in cattle
WO1988005823A3 (en) Mycobacterium tuberculosis genes encoding protein antigens
WO2001062893A3 (en) Compounds and methods for diagnosis and immunotherapy of tuberculosis
DK524289A (da) Fremgangsmaade til diagnosticering for og vaccine mod mycobakterier
WO2006104389A1 (en) Methods and means for diagnostics, prevention and treatment of mycobacterium infections and tuberculosis disease
BRPI0508722A (pt) proteìna recombinante, polinucleotìdeo, vetor de expressão e célula hospedeira recombinantes, composição imunogênica, uso de proteìna recombinante, composição de vacina, composição de droga, kit diagnóstico de, ou um kit para imunomonitorar, uma infecção com hpv, método para o diagnóstico in vitro ou para a imunomonitoração de uma infecção com hpv, uso de uma proteìna recombinante, e, processo para a triagem de epìtopos de células t crìticos desconhecidos ou sub-dominantes em um polipeptìdio
Collins et al. Diagnosis and epidemiology of bovine tuberculosis using molecular biological approaches
WO2003070187A3 (en) Fusion proteins of mycobacterium tuberculosis
Lin et al. Cross-reactive immunity to Mycobacterium tuberculosis DosR regulon-encoded antigens in individuals infected with environmental, nontuberculous mycobacteria
Roche et al. Human T‐cell epitopes on the Mycobacterium tuberculosis secreted protein MPT64
Dockrell et al. A postgenomic approach to identification of Mycobacterium leprae-specific peptides as T-cell reagents
BR0312437A (pt) Polipeptìdeo imunogênico isolado mycobacterium avium subspécie para tuberculosis e usos do mesmo
Mahmoudi et al. Cloning, expression and purification of Mycobacterium tuberculosis ESAT-6 and CFP-10 antigens
Triccas et al. Molecular and immunological analyses of the Mycobacterium avium homolog of the immunodominant Mycobacterium leprae 35-kilodalton protein
Mirlekar et al. Mycobacterium tuberculosis: approach to development of improved strategies for disease control through vaccination and immunodiagnosis
CN107530414B (zh) 区分活动性结核病和潜伏结核感染的结核分枝杆菌抗原及其应用
Chapeton‐Montes et al. Characterizing the Mycobacterium tuberculosis Rv2707 protein and determining its sequences which specifically bind to two human cell lines
Jain et al. Novel mutations in emb B gene of ethambutol resistant isolates of Mycobacterium tuberculosis: a preliminary report
Sürücüoğlu et al. The reliability of tuberculin skin test in the diagnosis of latent tuberculosis infection in psoriasis patients: a case‐control study
ATE306911T1 (de) Zusammensetzungen zum nachweis und zur diagnose von infektiösen mykobakteriellen krankheiten

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/09/2015, OBSERVADAS AS CONDICOES LEGAIS.